CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab

Rhea-AI Summary

CytoDyn (OTCQB: CYDY) closed a $17.5 million financing on March 5, 2026 to fund further development of leronlimab, its CCR5-targeting humanized monoclonal antibody being evaluated in oncology indications including TNBC and mCRC.

Net proceeds will primarily support ongoing and planned clinical trials, regulatory engagement, data analysis, manufacturing readiness, compliance infrastructure, and general working capital, and are expected to fund operations into 2027.

Positive

• $17.5 million gross proceeds closed
• Financing expected to fund operations into 2027
• Proceeds earmarked for clinical trials and regulatory engagement

Negative

• Financing may cause shareholder dilution
• Amount may be insufficient if trials expand or costs rise

News Market Reaction – CYDY

-2.69%

1 alert

-2.69% News Effect

On the day this news was published, CYDY declined 2.69%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

VANCOUVER, Washington, March 05, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has closed on a financing of $17.5 million in gross proceeds, with Paulson Investment Company acting as placement agent.

The demand from both new and current investors highlights confidence in CytoDyn’s clinical progress and its versatile development strategy in immuno-oncology, exploring a number of potential roles for leronlimab – the Company’s first-in-class humanized monoclonal antibody that targets the CCR5 receptor.

“The successful completion of this financing in a challenging capital markets environment reflects meaningful investor support for our clinical strategy,” said Robert E. Hoffman, CFO of CytoDyn. “The financing strengthens our balance sheet and is expected to fund current operations into 2027, supporting continued advancement of our clinical programs and strategic priorities. We appreciate the support of both new and existing investors, which underscores confidence in the continued development of leronlimab and its potential role in oncology, as we remain focused on disciplined execution and long-term value creation.”

Net proceeds from the financing will primarily support the advancement of CytoDyn’s clinical development programs, including ongoing and planned trials, regulatory engagement, and data analysis. Additional funds may be allocated toward manufacturing readiness, regulatory and compliance infrastructure, and general working capital.

For more information on the Company’s recent fundraising activities, including key terms and conditions of some of the agreements, please see CytoDyn’s filings with the Securities and Exchange Commission, including its Current Report on Form 8-K filed on March 5, 2026.

About CytoDyn

CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.

For more information, please visit www.cytodyn.com and follow us on LinkedIn.

Note Regarding Forward-Looking Statements

This news release may contain forward-looking statements relating to, among other things, the success of the fundraising initiative, the anticipated benefits and timelines discussed above, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.

Corporate Contact

CytoDyn Inc.
ir@cytodyn.com

Media Contacts

David Schull or Ignacio Guerrero-Ros, Ph.D.  
Russo Partners, LLC 
CytoDyn@russopartnersllc.com 

FAQ

How much financing did CytoDyn (CYDY) close on March 5, 2026?

CytoDyn closed a $17.5 million financing on March 5, 2026. According to the company, gross proceeds will support clinical development of leronlimab, regulatory engagement, data analysis, manufacturing readiness, compliance infrastructure, and general working capital.

What will the $17.5M financing mean for CYDY operations and runway?

The financing is expected to fund company operations into 2027. According to the company, net proceeds are intended to support ongoing and planned trials, regulatory activities, data analysis, manufacturing readiness, and general working capital needs.

How will the financing affect CytoDyn shareholders (CYDY)?

The financing may result in shareholder dilution depending on securities issued. According to the company, proceeds were raised to fund development; investors should review the company’s SEC filings for terms and potential dilutive effects.

What development programs will CYDY fund with the new financing?

Proceeds will primarily support clinical development programs for leronlimab in oncology. According to the company, funds target ongoing and planned trials, regulatory engagement, data analysis, manufacturing readiness, and compliance infrastructure.

Who acted as placement agent for CytoDyn's March 2026 financing (CYDY)?

Paulson Investment Company acted as placement agent for the financing. According to the company, demand came from both new and existing investors, reflecting confidence in CytoDyn’s clinical strategy for leronlimab.